Caribbean and Latin American healthcare market intelligence across 21 markets: pharmaceutical fieldwork, HCP research, patient recruitment, OTC and consumer healthcare, medical device studies, and diabetes therapeutic area research. Multilingual capability, four decades of regional specialization.
The Caribbean healthcare and pharmaceutical landscape combines features of mature regulated markets (Puerto Rico, Cayman Islands) and emerging markets (Haiti, Suriname) within a single regional footprint. Pharmaceutical research must navigate this heterogeneity: regulatory frameworks vary from US FDA-aligned (Puerto Rico, USVI) to UK MHRA-influenced (Cayman, BVI) to nationally independent CARICOM authorities to DIGEMAPS in the Dominican Republic.
Healthcare delivery models also vary materially. Public health system coverage spans full universal coverage (Bahamas, Trinidad and Tobago) to substantially private-pay markets (Cayman Islands, Bermuda) to dual public-private systems (Jamaica, Barbados, Dominican Republic). Physician density, hospital infrastructure, and pharmacy retail formats differ enough that single-market methodology rarely transfers directly across the region.
Disease prevalence patterns create research demand specific to the region. The Caribbean has one of the highest diabetes prevalence rates globally (12-15% in adult populations across multiple markets), elevated cardiovascular disease rates, and growing demand for OTC and consumer healthcare research as middle-class populations expand in the Dominican Republic, Jamaica, and Trinidad and Tobago.
For pharmaceutical companies, OTC manufacturers, medical device firms, and healthcare consulting partners, the Caribbean requires research methodology calibrated to multi-market diversity, multilingual fieldwork (English, Spanish, Dutch, French, Haitian Creole, Sranan Tongo), and regulatory pathway awareness that varies by jurisdiction.
Multi-market pharmaceutical fieldwork including physician surveys, patient research, pharmacy audits, and HCP advisory boards. Sample sizes from N=50 specialist physicians to N=2,000+ patient panels across regional studies. See our pharmaceutical fieldwork methodology for full sampling and execution detail.
Healthcare professional research targeting physicians, pharmacists, nurses, and allied health professionals across Caribbean and Latin American markets. Therapeutic-area-specific recruitment, prescribing pattern studies, and KOL identification. Detailed in our HCP research methodology.
Patient panel recruitment for surveys, interviews, ethnographic studies, and condition-specific research. Multi-channel sourcing including community health centers, patient advocacy networks, and digital recruitment. Our patient recruitment methodology covers sampling frames and consent protocols.
Specialist research in high-prevalence Caribbean conditions including diabetes, hypertension, cardiovascular disease, and oncology. ICD-10-mapped study design and condition-specific recruitment. Our Caribbean diabetes research methodology documents the framework applied across therapeutic areas.
Over-the-counter and consumer healthcare market research including pharmacy audits, shopper behavior, therapeutic category dynamics, and pharmacist recommendation studies. Detailed in our Caribbean OTC research methodology.
Medical device market research, diagnostic adoption studies, and healthcare technology evaluation across hospital and ambulatory care settings. Includes biomedical engineer surveys, hospital procurement research, and diagnostic device usage studies across Caribbean and Latin American markets.
Free Consultation
Scoped proposal delivered within 48 hours. Patient studies, HCP access, OTC, and market access research.
Our pharmaceutical and healthcare research operates across 21 Caribbean and Latin American markets. Country selection for a specific study depends on therapeutic area prevalence, regulatory pathway, market commercial value, and the client's strategic priorities.
| Market | Healthcare research strength | Primary language |
|---|---|---|
| Dominican Republic | Largest Caribbean pharma market | Spanish |
| Jamaica | Mature pharmacy retail, strong HCP networks | English |
| Trinidad and Tobago | Higher-income, premium therapeutic categories | English |
| Puerto Rico | US FDA-aligned regulatory | Spanish, English |
| Bahamas | High per-capita health expenditure | English |
| Barbados | Mature pharmacy and HCP infrastructure | English |
| Guyana | Rapid market expansion, oil economy | English |
| Suriname | Distinct Dutch regulatory environment | Dutch |
| Haiti | Largest French-language Caribbean market | French, Haitian Creole |
| Cayman Islands | High per-capita, private-pay market | English |
Plus: Curaçao, Aruba, USVI, BVI, Belize, Bermuda, Saint Maarten, Turks and Caicos, Martinique, Guadeloupe, Cuba.
Our healthcare and pharmaceutical methodology has been documented across five detailed methodology articles, each covering a specific research category. The methodology framework spans sampling design, recruitment protocols, fieldwork execution, data quality controls, and analytical approach calibrated to Caribbean market realities.
Methodology is calibrated per project to the client's commercial questions, regulatory context, and market priorities.
Healthcare and pharmaceutical market research in the Caribbean captures commercial intelligence for pharmaceutical, OTC, medical device, and healthcare services companies operating across the region's 21 markets. Research methodologies span patient surveys, healthcare professional studies, pharmacy and hospital audits, regulatory analysis, and competitive intelligence — calibrated to Caribbean market heterogeneity in regulatory frameworks, healthcare delivery models, and disease prevalence patterns including high-burden conditions such as diabetes, hypertension, and cardiovascular disease.
Hope Research Group conducts pharmaceutical and healthcare market research across 21 Caribbean and Latin American markets including the Dominican Republic, Jamaica, Trinidad and Tobago, Puerto Rico, Bahamas, Barbados, Guyana, Suriname, Haiti, Cayman Islands, the Eastern Caribbean OECS markets, Cuba, Curaçao, Aruba, USVI, BVI, Belize, Bermuda, Martinique, and Guadeloupe. Country selection per study depends on therapeutic area, regulatory pathway, and commercial priorities.
We specialize in pharmaceutical fieldwork, HCP research, patient recruitment, diabetes and therapeutic-area-specific studies, OTC and consumer healthcare research, and medical device research. Each research category has documented methodology covering sampling design, recruitment protocols, fieldwork execution, and analytical approach.
Physician and HCP recruitment uses multi-channel sourcing including national medical association lists, hospital and clinic networks, specialist society memberships, and direct outreach. Sample frames are stratified by specialty, hospital affiliation, and geography. Honoraria comply with both regional and global pharma compliance standards including ICC/ESOMAR and IFPMA codes.
Caribbean pharmaceutical research differs in three structural ways: multi-market heterogeneity within a single regional footprint requires per-market methodology calibration; multilingual fieldwork (English, Spanish, Dutch, French, Haitian Creole, Sranan Tongo) is standard; and regulatory pathway diversity (US FDA-aligned, UK MHRA-influenced, CARICOM national, DIGEMAPS) means market entry and approval research must address jurisdiction-specific requirements.
Yes. Multi-market regional studies are our specialty. Typical regional study designs sample 3-6 markets representing the regional diversity, with country-level reporting plus regional aggregation. Sample sizes typically run N=200-500 per market for HCP studies and N=400-800 per market for patient research, scaled to the commercial questions.
English for CARICOM markets including Jamaica, Trinidad and Tobago, Barbados, Bahamas, and Guyana. Spanish for Dominican Republic, Cuba, Puerto Rico, and regional bilingual contexts. Dutch and Sranan Tongo for Suriname. French and Haitian Creole for Haiti and the French Antilles. Bilingual instruments and bilingual interviewers are standard for cross-language studies.
Our research operations comply with ICC/ESOMAR International Code, IFPMA Code of Practice, and applicable national regulations including CARICOM pharmaceutical regulations, DIGEMAPS (Dominican Republic), and Puerto Rico FDA-aligned frameworks. Study designs include informed consent protocols, data privacy compliance, and adverse event reporting workflows where applicable. Specific regulatory pathway documentation is provided per project upon request.
Partner with healthcare research experts who understand Caribbean and LATAM health markets.